Travere Therapeutics, Inc. Common Stock
TVTX Real Time Price USDRecent trades of TVTX by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in TVTX holdings by institutional investors
Quarterly net insider trading by TVTX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for TVTX
21 former government officials from 12 congressional offices at 5 lobbying firms have lobbied for TVTX, most recently Apr 17, 2026.
-
Alanna Temme House Legislative Director, U.S. Representative Jon Porter -
Adam Navara House New Legislative Fellow, Rep. Jan Schakowsky. -
Charles Dujon House Legislative Director (1998-2013), Rep. Jesse Jackson, Jr. -
Mark Mioduski House Prof Staff; House Approps Cmte (Obey)
-
Karyn Richman House Program Examiner, Executive Office of the President, Office of Management and Budget; Professional Staff, House Appropriations Committee
-
Michael Mioduski (Name Error-Not A Real Person) House New Prof Staff; House Approps Cmte (Obey)
-
Carolyn Smith Congress New Associate Deputy Chief of Staff & Legislative Counsel, Joint Committee on Tax.
-
James Paluskiewicz House New Chief Counsel, House Health Subcommittee; Professional Staff, House Energy & Commerce Committee; Legislative Dir./Dep. Chief of Staff, Rep. Michael Burgess; Legislative Dir., Rep. Charlie Norwood; Legislative Correspondent, Rep. Stephanie Tubbs Jones
TVTX Estimated quarterly lobbying spending
TVTX Revenue by Segment or Geography
New TVTX patent grants
-
Patent Title: Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders Aug. 25, 2026
-
Patent Title: Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases Dec. 28, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded to TVTX from public contracts
Recent insights relating to TVTX
Recent picks made for TVTX stock on CNBC
ETFs with the largest estimated holdings in TVTX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $TVTX stock a Buy, Sell, or Hold?
- What is the price target for $TVTX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $TVTX stock?
- Who owns the most shares of $TVTX stock?
- What funds own $TVTX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TVTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Address San Diego, CA
- Market Cap 4.9 billion
- Employees 497
- Industrial Classification Pharmaceutical Preparations
Travere Therapeutics, Inc. Common Stock (TVTX) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Travere Therapeutics, Inc. Common Stock (TVTX).
Quiver Premium charts TVTX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at TVTX, per a recent SEC DEF 14A filing. We estimate that the median employee at Travere Therapeutics, Inc. is paid $310,735.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|